Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
In 2013 brimonidine tartrate gel 0.33% (Mirvaso Gel, Galderma Laboratories, LP, Fort Worth, TX) was approved by the US Food and Drug Administration for the treatment of facial erythema of rosacea. It is the first and only drug on the market to address the hallmark redness of this chronic, inflammatory disease. Commonly reported adverse events include erythema/flushing worse than at baseline, most often occurring with the first application. We report a unique case of facial erythema of rosacea that responded to brimonidine gel with effective blanching for two years until the patient developed a paradoxical erythema reaction. This is an adverse reaction physicians should be aware of with continued prescription of brimonidine gel for their rosacea patients.<br /><br /> <em>J Drugs Dermatol</em>. 2016;15(6):763-765.
Erin
E
Lowe
Scott
S
Lim
D000279:Administration, Cutaneous; D000328:Adult; D000068438:Brimonidine Tartrate / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced* / Q000175:diagnosis*; D005260:Female; D005782:Gels; D006801:Humans; D012393:Rosacea / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D005782:Gels; D000068438:Brimonidine Tartrate